Join Forte Biosciences for a conference call to discuss positive data from a Phase 1b trial in celiac disease for lead program FB102 (FB102-101), featuring Prof. Jason Tye-Din, Head of Celiac Research at the Walter and Eliza Hall Institute and principal investigator in the FB102-101 study.